SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 198 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,611,114 | -53.3% | 2,686,085 | +1.1% | 0.00% | – |
| Q2 2023 | $3,452,315 | -78.1% | 2,655,627 | -70.4% | 0.00% | -100.0% |
| Q1 2023 | $15,770,617 | -74.3% | 8,960,578 | -54.2% | 0.00% | -50.0% |
| Q4 2022 | $61,474,192 | +80.0% | 19,577,768 | +181.0% | 0.00% | 0.0% |
| Q3 2022 | $34,145,000 | +6.6% | 6,968,276 | -10.0% | 0.00% | 0.0% |
| Q2 2022 | $32,041,000 | -29.1% | 7,739,471 | -0.5% | 0.00% | 0.0% |
| Q1 2022 | $45,175,000 | -2.9% | 7,775,327 | +25.3% | 0.00% | 0.0% |
| Q4 2021 | $46,534,000 | -12.0% | 6,204,587 | +5.7% | 0.00% | -33.3% |
| Q3 2021 | $52,886,000 | -26.3% | 5,869,755 | -2.1% | 0.00% | -25.0% |
| Q2 2021 | $71,750,000 | -12.5% | 5,994,166 | -8.4% | 0.00% | -20.0% |
| Q1 2021 | $81,980,000 | -17.6% | 6,542,667 | +2.6% | 0.01% | -16.7% |
| Q4 2020 | $99,514,000 | +49.9% | 6,377,057 | -9.2% | 0.01% | +20.0% |
| Q3 2020 | $66,388,000 | +14.2% | 7,025,167 | +8.3% | 0.01% | +25.0% |
| Q2 2020 | $58,141,000 | +88.3% | 6,488,918 | +33.9% | 0.00% | +33.3% |
| Q1 2020 | $30,880,000 | -23.4% | 4,847,768 | +0.7% | 0.00% | 0.0% |
| Q4 2019 | $40,298,000 | -11.3% | 4,814,626 | -4.1% | 0.00% | 0.0% |
| Q3 2019 | $45,423,000 | -21.1% | 5,019,076 | -6.1% | 0.00% | -25.0% |
| Q2 2019 | $57,597,000 | +3.2% | 5,347,908 | -8.6% | 0.00% | 0.0% |
| Q1 2019 | $55,834,000 | -17.7% | 5,852,641 | -1.0% | 0.00% | -33.3% |
| Q4 2018 | $67,849,000 | -38.5% | 5,910,152 | -9.3% | 0.01% | -25.0% |
| Q3 2018 | $110,392,000 | +27.8% | 6,512,627 | +7.1% | 0.01% | +14.3% |
| Q2 2018 | $86,346,000 | +0.2% | 6,080,644 | +34.0% | 0.01% | 0.0% |
| Q1 2018 | $86,206,000 | +32.1% | 4,536,951 | +14.0% | 0.01% | +40.0% |
| Q4 2017 | $65,268,000 | +50.5% | 3,979,593 | +37.7% | 0.01% | +25.0% |
| Q3 2017 | $43,373,000 | +163.8% | 2,890,810 | +54.7% | 0.00% | +300.0% |
| Q2 2017 | $16,441,000 | +156.5% | 1,868,285 | +51.6% | 0.00% | 0.0% |
| Q1 2017 | $6,409,000 | +77.3% | 1,231,989 | +3.8% | 0.00% | – |
| Q4 2016 | $3,614,000 | -67.8% | 1,186,569 | -51.1% | 0.00% | -100.0% |
| Q3 2016 | $11,231,000 | +1.7% | 2,426,552 | +27.2% | 0.00% | 0.0% |
| Q2 2016 | $11,042,000 | -18.9% | 1,906,940 | -15.3% | 0.00% | 0.0% |
| Q1 2016 | $13,622,000 | -19.6% | 2,251,763 | +21.4% | 0.00% | -50.0% |
| Q4 2015 | $16,934,000 | -29.0% | 1,854,666 | -56.1% | 0.00% | -33.3% |
| Q3 2015 | $23,853,000 | -36.8% | 4,229,198 | +24.4% | 0.00% | -25.0% |
| Q2 2015 | $37,720,000 | -4.4% | 3,400,985 | +35.1% | 0.00% | 0.0% |
| Q1 2015 | $39,472,000 | +11.5% | 2,517,383 | +8.2% | 0.00% | 0.0% |
| Q4 2014 | $35,404,000 | +29.6% | 2,327,109 | -8.1% | 0.00% | +33.3% |
| Q3 2014 | $27,318,000 | -15.6% | 2,533,186 | +19.5% | 0.00% | 0.0% |
| Q2 2014 | $32,379,000 | -5.8% | 2,120,350 | +11.5% | 0.00% | -25.0% |
| Q1 2014 | $34,378,000 | -7.1% | 1,901,499 | -40.2% | 0.00% | +100.0% |
| Q4 2013 | $37,016,000 | +63.6% | 3,180,142 | +47.3% | 0.00% | -33.3% |
| Q3 2013 | $22,623,000 | +6.5% | 2,158,797 | -20.6% | 0.00% | 0.0% |
| Q2 2013 | $21,245,000 | – | 2,720,026 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |